Advanced case of PKDL due to delayed treatment: A rare case report.

Roshan Kamal TopnoVidya Nand Rabi Das Maneesh KumarMajor MadhukarKrishna PandeyNeena VermaKanhaiya AgrawalChandra Shekhar LalNiyamat Ali SiddiquiSanjiva BimalPradeep Das

Published in: PLoS neglected tropical diseases (2020)

Post-kala-azar dermal leishmaniasis (PKDL) is clinical outcome of visceral leishmaniasis (VL) and is thought to be the potential reservoir of parasite. Miltefosine (MF) is the only oral drug existing for treatment of post-kala-azar dermal leishmaniasis (PKDL). Increased miltefosine tolerance in clinical isolates of Leishmania donovani has been reported and is one of the major concerns in the treatment of PKDL. Here, we report a highly ulcerated PKDL case that was successfully cured after miltefosine treatment.

Keyphrases

case report
climate change
adverse drug